Idiopathic pulmonary fibrosis (IPF) is a devastatingly progressive disease, characterized by a prognosis worse than many cancers, with a median survival of 3 years. Recent data suggests that Northern Ireland has one of the highest prevalence of IPF in the UK. Over the past decade, there has been a cohesive effort from patients, physicians, scientists and industry partners to find definitive treatments for IPF. Treatment aims have shifted from reversing the disease to slowing or preventing progression.

Two effective antifbrotic therapies are now available which offer hope to patients in slowing the inexorable decline in lung function. Pirfenidone (Esbriet®) a pleiotropic molecule that has antifibrotic, anti-inflammatory and antioxidant effects and Nintedanib (Ofev®) a tyrosine Kinase Inhibitor with potent triple inhibitory properties including activity directed against PDGF, vascular endothelial growth-factor, and fibroblast growth-factor receptors. Pooled analysis of the ASCEND and CAPACITY trials and subgroup analysis of the INPULSIS and TOMORROW trials demonstrate effectiveness in mild disease, currently not recommended by NICE.^[@cit0001]^ IPF is often misdiagnosed as COPD as the majority of patients are ex-smokers. For these reasons early and accurate diagnosis of IPF is of paramount importance and requires expertise and multidisciplinary input.

At present there are 8 compounds undergoing phase 2 clinical trials, as well as trials exploring combination therapy with available antifibrotics concomitantly in addition to sildenafil.^[@cit0002]^ There is inequity of treatment for Northern Irish IPF patients in comparison to the rest of the UK as our uptake of currently available antifibrotics has been poor and at present patients do not have access to untested novel treatments. Given the similarities to a cancer, difficulties in securing an accurate diagnosis and limited treatment strategies currently available in NI, a regional centre is urgently needed.
